Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Gross Margin of 77.94% for Q1 2026, down 120.0% year-over-year from 389.71% in Q1 2025, and down 9.2% on a QoQ basis from 85.84% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Margin data on file, last reported at 77.94% in Q1 2026.
- Quarterly Gross Margin fell 120.0% year-over-year to 77.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83.52% (down 149.0% YoY) and the FY2025 annual result came in at 83.8%, down 245.0% from the prior year.
- Gross Margin eased to 77.94% in Q1 2026 per RARE's latest filing, from 85.84% in the prior quarter.
- Across five years, Gross Margin topped out at 94.85% in Q4 2022 and bottomed at 77.94% in Q1 2026.
- The 5-year median for Gross Margin is 87.8% (2023), against an average of 87.18%.
- The widest annual swing landed in 2022, when Gross Margin plunged 565 bps; it then soared 66 bps in 2025.
- Tracing RARE's Gross Margin over 5 years: stood at 94.85% in 2022, then dropped by 4 bps to 90.69% in 2023, then retreated by 1 bps to 89.57% in 2024, then dropped by 4 bps to 85.84% in 2025, then dropped by 9 bps to 77.94% in 2026.
- Per Business Quant, the three latest RARE Gross Margin figures stand at 77.94% (Q1 2026), 85.84% (Q4 2025), and 82.5% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 77.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.94% |
| Dec 31, 2025 | 85.84% |
| Sep 30, 2025 | 82.50% |
| Jun 30, 2025 | 86.18% |
| Mar 31, 2025 | 79.14% |
| Dec 31, 2024 | 89.57% |
| Sep 30, 2024 | 84.93% |
| Jun 30, 2024 | 85.53% |
| Mar 31, 2024 | 83.89% |
| Dec 31, 2023 | 90.69% |
| Sep 30, 2023 | 88.79% |
| Jun 30, 2023 | 90.85% |
| Mar 31, 2023 | 87.80% |
| Dec 31, 2022 | 94.85% |
| Sep 30, 2022 | 90.48% |
| Jun 30, 2022 | 90.74% |
| Mar 31, 2022 | 92.37% |
| Dec 31, 2021 | 95.79% |
| Sep 30, 2021 | 94.89% |
| Jun 30, 2021 | 96.39% |
| Mar 31, 2021 | 94.78% |
| Dec 31, 2020 | 94.01% |
| Sep 30, 2020 | 97.12% |
| Jun 30, 2020 | 97.08% |
| Mar 31, 2020 | 90.35% |
| Dec 31, 2019 | 85.65% |
| Sep 30, 2019 | 89.60% |
| Jun 30, 2019 | 96.83% |
| Mar 31, 2019 | 97.51% |
| Dec 31, 2018 | 96.88% |
| Sep 30, 2018 | 97.68% |
| Jun 30, 2018 | 98.90% |
| Mar 31, 2018 | 97.89% |